Search

Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment

US FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes

Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway

Jardiance® (empagliflozin) Tablets Studied in CKD | Boehringer Ingelheim US

BI & Eli Lilly & Co. announce plans for a new trial investigating JARDIANCE for the treatment of CKD. View ISI, PI and Med Guide.

Interchangeable Biosimilar Now on Express Scripts® Formulary

Boehringer Ingelheim’s Interchangeable biosimilar now included on Express Scripts National Preferred Formulary

Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm)

BI to Donate 75k Rabies Vaccine Doses | Boehringer Ingelheim US

Boehringer Ingelheim to donate 75,000 doses of IMRAB® vaccine to the Global Alliance for Rabies Control through shots for Good Initiative.

Introducing Ingelvac Provenza™ | Boehringer Ingelheim US

Find out more on our new swine vaccine, offering increased protection against influenza strains affecting 70% of growing pigs annually.

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies

Boehringer Ingelheim and Lilly expand heart failure program for Jardiance with new exercise capacity trials

Results announced from EMPACT-MI phase III trial

Results announced from EMPACT-MI phase III trial in adults following a heart attack.

A Holistic Approach to Cardio-Renal-Metabolic Care | Boehringer Ingelheim US

Our Blueprint for Constructing a Holistic Approach to Cardio-renal-metabolic Care

Low-WAC interchangeable biosimilar is now available

Adalimumab-adbm, our interchangeable biosimilar to Humira, now available at a low wholesale acquisition cost.

Jardiance® (empagliflozin) analysis reinforces established safety profile

Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis

Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride

Management Rotation

Click here to read testimonies from our employees who enrolled in our management rotation program.

Pushing for Progress

Growing fresh produce for a cause at our U.S. headquarters

Leadership insights about our focus on patient centricity

Read about our patient-centric approach in discovering and developing medicines that transform patients’ lives from the point of view of Keri Yale, our head of patient centricity and engagement

Interview with Norbert Kraut: How cancer drives us forward

Norbert Kraut, our Global Head of Cancer Research at Boehringer Ingelheim, shares our approach to advancing cancer research and exploring new technologies

Supply Chain Scholarship for Cowtribe

A supply chain course we sponsored boosted the career of Latifa Saaka

Disentangling Fibrosis: Finding ways to fix ‘repair gone wrong’

Biosimilars

Top-line Phase II Data for treatment of MASH

Boehringer Ingelheim and Zealand Pharma announced top-line Phase II data for treatment of metabolic dysfuntion-associated steatohepatitis (MASH).

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers